Acute Myelocytic Leukemia

Search Trials
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Not yet recruiting
Last Changed:
Oct 22, 2021
First Changed:
Oct 14, 2021
Disease(s):
AML, Childhood
Intervention(s):
CD33*CD3 BsAb
Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination With Conventional Chemotherapy
Status:
Not yet recruiting
Last Changed:
Nov 1, 2021
First Changed:
Nov 1, 2021
Disease(s):
Acute Myeloid Leukemia
Intervention(s):
TalazoparibTopotecanGemcitabine
A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS
Status:
Active, not recruiting
Last Changed:
Oct 18, 2021
First Changed:
Jul 2, 2015
Disease(s):
Acute Myeloid Leukemia
Intervention(s):
BemcentinibCytarabineDecitabine
PRGN-3006 Adoptive Cellular Therapy for Relapsed or Refractory AML or High Risk MDS
Status:
Recruiting
Last Changed:
Oct 19, 2021
First Changed:
Apr 25, 2019
Disease(s):
Acute Myeloid Leukemia
Intervention(s):
PRGN-3006 T Cells

Connect. Empower. Inspire.